New data shows that Pharmacyclics and partner Janssen’s Imbruvica (ibrutinib) provides ongoing control of Waldenstrom’s macroglobulinemia (WM). Investigators from Dana-Farber Cancer Institute reported that the most recent results from a clinical trial show that ibrutinib continued to control the rare blood cancer, with 95 percent of patients surviving for two …